PANACEA BIOTEC LTD. - 531349 - Shareholding for the Period Ended March 31, 2019
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here20-04-2019
20-04-2019
PANACEA BIOTEC LTD. - 531349 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half-Year Ended 31St March, 2019
Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certified copy of certificate from M/s. R & D, Company Secretaries, for the half-year ended 31st March, 2019, confirming that all the transfers of shares have been completed within the stipulated time. This is for your kind information and record please.17-04-2019
PANACEA BIOTEC LTD. - 531349 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Vinod GoelDesignation :- Company Secretary and Compliance Officer17-04-2019
Panacea Biotec Ltd - 531349 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vistra ITCL India Ltd10-04-2019
Panacea Biotec rallies over 10% on Rs 992 cr investment from IndiaRF
Shares of Panacea Biotec Ltd rose as much as 17.50 per cent intra-day, as the company said on Monday that India Resurgence Fund (IndiaRF) has announced an investment of up to $144 million in the company.09-04-2019
PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vistra ITCL India Ltd09-04-2019
PANACEA BIOTEC LTD. - 531349 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the information pertaining to issue of duplicate share certificate to the shareholder consequent to loss of share certificate being reported by the shareholder.09-04-2019
PANACEA BIOTEC LTD. - 531349 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is in continuation to our letters dated February 26, 2019 and February 27, 2019 intimating about the One time settlement ('OTS') with the consortium of lenders of the Company. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would now like to inform you that the Company has done OTS with the consortium lenders and details of the same are attached. We request you to kindly bring the above information to the notice of your members.09-04-2019
PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt Ltd09-04-2019
Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec is delighted to attach a copy of joint press release titled 'IndiaRF Announces USD 144 million Investment in Panacea Biotec Ltd.' in this regard. India Resurgence Fund ('IndiaRF'), promoted by Piramal Enterprises Limited and Bain Capital Credit, along with its affiliates has announced an investment of up to INR 992 Crores/ USD 144 Million in Panacea Biotec Limited. The investment proceeds will be used for a one-time settlement with existing lenders, general working capital and growth requirements of the Company. This investment is structured by way of NCDs of up to INR 864 Crores and subscription amount of INR 32 Crores towards share warrants to be allotted on a preferential basis.08-04-2019